• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管生成抑制剂内皮抑素1.5埃分辨率的晶体结构。

Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution.

作者信息

Hohenester E, Sasaki T, Olsen B R, Timpl R

机构信息

Department of Crystallography, Birkbeck College, London WC1E 7HX, UK. e.hohenester.cryst.bbk.ac.uk

出版信息

EMBO J. 1998 Mar 16;17(6):1656-64. doi: 10.1093/emboj/17.6.1656.

DOI:10.1093/emboj/17.6.1656
PMID:9501087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1170513/
Abstract

A number of extracellular proteins contain cryptic inhibitors of angiogenesis. Endostatin is a 20 kDa C-terminal proteolytic fragment of collagen XVIII that potently inhibits endothelial cell proliferation and angiogenesis. Therapy of experimental cancer with endostatin leads to tumour dormancy and does not induce resistance. We have expressed recombinant mouse endostatin and determined its crystal structure at 1.5 A resolution. The structure reveals a compact fold distantly related to the C-type lectin carbohydrate recognition domain and the hyaluronan-binding Link module. The high affinity of endostatin for heparin is explained by the presence of an extensive basic patch formed by 11 arginine residues. Endostatin may inhibit angiogenesis by binding to the heparan sulphate proteoglycans involved in growth factor signalling.

摘要

许多细胞外蛋白含有潜在的血管生成抑制剂。内皮抑素是胶原蛋白XVIII的一个20 kDa C端蛋白水解片段,能有效抑制内皮细胞增殖和血管生成。用内皮抑素治疗实验性癌症可导致肿瘤休眠,且不会诱导耐药性。我们已表达重组小鼠内皮抑素,并以1.5埃的分辨率确定了其晶体结构。该结构揭示了一种紧密折叠,与C型凝集素碳水化合物识别结构域和透明质酸结合Link模块有较远的关系。内皮抑素对肝素的高亲和力可通过由11个精氨酸残基形成的广泛碱性区域来解释。内皮抑素可能通过与参与生长因子信号传导的硫酸乙酰肝素蛋白聚糖结合来抑制血管生成。

相似文献

1
Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution.血管生成抑制剂内皮抑素1.5埃分辨率的晶体结构。
EMBO J. 1998 Mar 16;17(6):1656-64. doi: 10.1093/emboj/17.6.1656.
2
Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity.源自胶原蛋白XV和XVIII的内皮抑素在结构和结合特性、组织分布及抗血管生成活性方面存在差异。
J Mol Biol. 2000 Sep 1;301(5):1179-90. doi: 10.1006/jmbi.2000.3996.
3
Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin.包含血管生成抑制剂内皮抑素的胶原蛋白XVIII C末端球状结构域的结构、功能及组织形式
EMBO J. 1998 Aug 3;17(15):4249-56. doi: 10.1093/emboj/17.15.4249.
4
Collagen XVIII/endostatin structure and functional role in angiogenesis.胶原蛋白 XVIII/内皮抑素在血管生成中的结构与功能作用
Cell Struct Funct. 2000 Apr;25(2):97-101. doi: 10.1247/csf.25.97.
5
Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.肝素/硫酸乙酰肝素与血管生成抑制剂内皮抑素结合的结构基础及潜在作用
EMBO J. 1999 Nov 15;18(22):6240-8. doi: 10.1093/emboj/18.22.6240.
6
Structure and function of collagen-derived endostatin inhibitors of angiogenesis.胶原蛋白衍生的血管生成内皮抑素抑制剂的结构与功能
IUBMB Life. 2002 Feb;53(2):77-84. doi: 10.1080/15216540211466.
7
Variable zinc coordination in endostatin.内皮抑素中锌的可变配位
J Mol Biol. 2000 Mar 17;297(1):1-6. doi: 10.1006/jmbi.2000.3553.
8
The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.内皮抑素的最小活性结构域是一个肝素结合基序,可介导对肿瘤血管生成的抑制作用。
Cancer Res. 2004 Dec 15;64(24):9012-7. doi: 10.1158/0008-5472.CAN-04-2172.
9
Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV.人血浆内皮抑素的新型糖基化形式及胶原蛋白XV的循环内皮抑素相关片段。
Biochemistry. 1999 Aug 10;38(32):10217-24. doi: 10.1021/bi990787+.
10
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.内皮抑素:一种血管生成和肿瘤生长的内源性抑制剂。
Cell. 1997 Jan 24;88(2):277-85. doi: 10.1016/s0092-8674(00)81848-6.

引用本文的文献

1
Proteoglycans of basement membranes: Crucial controllers of angiogenesis, neurogenesis, and autophagy.基底膜蛋白聚糖:血管生成、神经发生和自噬的关键调控因子。
Proteoglycan Res. 2024 Jul-Sep;2(3). doi: 10.1002/pgr2.22. Epub 2024 Jun 29.
2
Variations of VEGFR2 Chemical Space: Stimulator and Inhibitory Peptides.VEGFR2 化学空间的变化:刺激肽和抑制肽。
Int J Mol Sci. 2024 Jul 16;25(14):7787. doi: 10.3390/ijms25147787.
3
Endostatin in Renal and Cardiovascular Diseases.内皮抑素在肾脏和心血管疾病中的作用
Kidney Dis (Basel). 2021 Sep 9;7(6):468-481. doi: 10.1159/000518221. eCollection 2021 Nov.
4
TargetAntiAngio: A Sequence-Based Tool for the Prediction and Analysis of Anti-Angiogenic Peptides.TargetAntiAngio:一种基于序列的抗血管生成肽预测和分析工具。
Int J Mol Sci. 2019 Jun 17;20(12):2950. doi: 10.3390/ijms20122950.
5
The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering.重组内皮抑素临床应用中的挑战:聚焦不同表达系统与分子生物工程
Adv Pharm Bull. 2017 Apr;7(1):21-34. doi: 10.15171/apb.2017.004. Epub 2017 Apr 13.
6
Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.内皮抑素和内皮抑素原:相似的血管生成抑制性抗癌因子的共同作用途径。
Adv Drug Deliv Rev. 2016 Feb 1;97:156-73. doi: 10.1016/j.addr.2015.10.012. Epub 2015 Oct 27.
7
Endostatin: A novel inhibitor of androgen receptor function in prostate cancer.内皮抑素:前列腺癌中雄激素受体功能的新型抑制剂。
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1392-7. doi: 10.1073/pnas.1417660112. Epub 2015 Jan 20.
8
Tunicate cytostatic factor TC14-3 induces a polycomb group gene and histone modification through Ca(2+) binding and protein dimerization.被囊类细胞生长抑制因子TC14-3通过钙离子结合和蛋白质二聚作用诱导多梳蛋白家族基因和组蛋白修饰。
BMC Cell Biol. 2012 Feb 2;13:3. doi: 10.1186/1471-2121-13-3.
9
CLT1 targets angiogenic endothelium through CLIC1 and fibronectin.CLT1 通过 CLIC1 和纤维连接蛋白靶向血管生成内皮细胞。
Angiogenesis. 2012 Mar;15(1):115-29. doi: 10.1007/s10456-011-9247-8. Epub 2011 Dec 28.
10
Novel pathogenic mutations and skin biopsy analysis in Knobloch syndrome.诺布罗赫综合征的新型致病突变与皮肤活检分析
Mol Vis. 2009;15:801-9. Epub 2009 Apr 23.

本文引用的文献

1
Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis.八片拼图:细胞外蛋白的生物活性片段作为血管生成的调节剂。
Trends Cell Biol. 1997 May;7(5):182-6. doi: 10.1016/S0962-8924(97)01037-4.
2
Phase combination and cross validation in iterated density-modification calculations.迭代密度修正计算中的相位组合与交叉验证
Acta Crystallogr D Biol Crystallogr. 1996 Jan 1;52(Pt 1):43-8. doi: 10.1107/S090744499500761X.
3
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.实验性癌症的抗血管生成疗法不会诱导获得性耐药。
Nature. 1997 Nov 27;390(6658):404-7. doi: 10.1038/37126.
4
Properties of the extracellular calcium binding module of the proteoglycan testican.蛋白聚糖testican细胞外钙结合模块的特性
FEBS Lett. 1997 Sep 15;414(3):557-61. doi: 10.1016/s0014-5793(97)01070-3.
5
Molecular mechanisms of blood vessel formation.血管形成的分子机制
Trends Biochem Sci. 1997 Jul;22(7):251-6. doi: 10.1016/s0968-0004(97)01074-8.
6
Pattern and spacing of basic amino acids in heparin binding sites.肝素结合位点中碱性氨基酸的模式与间距
Arch Biochem Biophys. 1997 Jul 1;343(1):92-100. doi: 10.1006/abbi.1997.0147.
7
Heparin-induced self-association of fibroblast growth factor-2. Evidence for two oligomerization processes.肝素诱导的成纤维细胞生长因子-2自身缔合。两种寡聚化过程的证据。
J Biol Chem. 1997 Jun 27;272(26):16382-9. doi: 10.1074/jbc.272.26.16382.
8
Vascular development: cellular and molecular regulation.血管发育:细胞与分子调控
FASEB J. 1997 Apr;11(5):365-73.
9
Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor.正确定向的肝素-十糖诱导二聚体是碱性成纤维细胞生长因子的生物活性形式。
Biochemistry. 1997 Apr 22;36(16):4782-91. doi: 10.1021/bi9625455.
10
Mechanisms of angiogenesis.血管生成的机制。
Nature. 1997 Apr 17;386(6626):671-4. doi: 10.1038/386671a0.